Reference 2018-765

REF:            2018-765

Subject:        Wet age-related macular degeneration policy

  

Request:        

  1. Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration?  If yes please supply a copy of your policy.

 

 

Response:

No.